FDA Warning Letter to Chinese Peptide Manufacturer: What It Means for Supply Chain Quality

In April 2026, the FDA issued a warning letter to Hangzhou Yiqi, a Chinese manufacturer of bulk peptide ingredients, citing manufacturing quality deficiencies. The action highlights the supply chain risks in the research peptide market and the importance of sourcing from qualityverified suppliers.

For research use only. Not for human consumption.